Could Biomerica Inc (NASDAQ:BMRA) Change Direction After Less Shorts?

May 18, 2018 - By Deanna Todd

Biomerica, Inc. (NASDAQ:BMRA) Logo

Investors sentiment increased to 1 in 2017 Q4. Its up 0.75, from 0.25 in 2017Q3. It improved, as 2 investors sold Biomerica, Inc. shares while 2 reduced holdings. 4 funds opened positions while 0 raised stakes. 109,831 shares or 64.71% more from 66,682 shares in 2017Q3 were reported.
6,347 were reported by Panagora Asset Management Incorporated. Vanguard Group Incorporated reported 79,642 shares. Retail Bank Of America De holds 0% or 3,832 shares. Deutsche Natl Bank Ag reported 2,200 shares. Millennium Mngmt Ltd Limited Liability Company has 11,167 shares. Wells Fargo Mn owns 6,500 shares. Tower Capital Ltd Liability Corporation (Trc) has 0% invested in Biomerica, Inc. (NASDAQ:BMRA) for 142 shares. Morgan Stanley has 0% invested in Biomerica, Inc. (NASDAQ:BMRA).

Since January 23, 2018, it had 4 insider purchases, and 0 insider sales for $65,333 activity. 11,800 shares valued at $49,324 were bought by CANO FRANCIS on Wednesday, January 24.

The stock of Biomerica Inc (NASDAQ:BMRA) registered a decrease of 19.35% in short interest. BMRA’s total short interest was 34,600 shares in May as published by FINRA. Its down 19.35% from 42,900 shares, reported previously. With 44,500 shares average volume, it will take short sellers 1 days to cover their BMRA’s short positions. The short interest to Biomerica Inc’s float is 0.58%.

The stock increased 2.23% or $0.08 during the last trading session, reaching $3.67. About 5,000 shares traded. Biomerica, Inc. (NASDAQ:BMRA) has risen 113.88% since May 18, 2017 and is uptrending. It has outperformed by 102.33% the S&P500.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $31.75 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

Another recent and important Biomerica, Inc. (NASDAQ:BMRA) news was published by Globenewswire.com which published an article titled: “Biomerica adds Harry Leider, MD, MBA to Strategic Advisory Board” on April 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.